Clinical Trial

Development of a Clinical-epidemiological Score Predictive of Tuberculosis.

Study acronym: SCORE-TB
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Despite being a curable and preventable disease, tuberculosis still represents a major global health problem. It is estimated that 10.8 million people contracted tuberculosis in 2023, with an incidence of 134 per 100,000 inhabitants. In 2023, there were 1.25 million deaths, confirming this disease as a leading cause of death and the leading cause of death from a single infectious agent. It is a disease that primarily affects adults in their most productive years, with significant repercussions on family budgets. The aim of this study is to identify and characterize the demographic, epidemiological, microbiological, clinical, and radiological variables of the tuberculosis population that has come to our hospital's attention, as an exemplary population in a low-endemic setting. This study also aims to develop a tuberculosis risk score aimed at early differentiation between patients requiring respiratory isolation and those with negligible tuberculosis risk, and to improve diagnostic accuracy.
Trial Details
NCT Number NCT07485868
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Tuberculosis
Enrollment 686 participants
Start Date 2026-04-01
Primary Completion 2030-04-01 (estimated)
Study Completion 2030-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-20